Skip to content

Clinical trials

Phase 2 Schizophrenia trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Schizophrenia Phase: Phase 2 Country / region: United States Clear all

207 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20026
20036
20049
200510
20069
200714
200815
200918
20108
20119
20129
20138
201412
20158
20166
20176
20186
20198
20209
20212
20227
20233
20244
20255
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed156
Terminated29
Recruiting10
Withdrawn5
Active, not recruiting3
Unknown status3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Yale University9
Otsuka Pharmaceutical Development & Commercialization, Inc.8
Nathan Kline Institute for Psychiatric Research7
Pfizer6
AbbVie5
GlaxoSmithKline5
Hoffmann-La Roche5
University of Maryland, Baltimore5
AstraZeneca4
Boehringer Ingelheim4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Schizophrenia207
Psychotic Disorders62
Mental Disorders22
Bipolar Disorder11
Cognitive Dysfunction11
Hallucinations5
Major Depressive Disorder5
Schizophrenia Spectrum and Other Psychotic Disorders5
Cognition Disorders4
Nervous System Diseases4

Trials

Showing 1 to 25 of 207. Each trial links to its page on Pharma Observatory.

107 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.